Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.41 |
| ▸ | ULK1 | O75385 | 7/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13406588 | 0.83 | PKM (0.41) | PKMULK1PTK2PTK2BCDK1 | |
| SCHEMBL3279901 | 0.83 | PKM (0.42) | PKMULK1PTK2PTK2BCDK1 | |
| SCHEMBL13387248 | 0.81 | KDR (0.35) | PTK2MAPTLMNA | |
| SCHEMBL13386894 | 0.80 | HTR6 (0.37) | PTK2ALDH1A1MAPT | |
| SCHEMBL13386895 | 0.78 | PTK2 (0.43) | ULK1PTK2PTK2BSYK | |
| SCHEMBL13951470 | 0.75 | HTR6 (0.36) | PTK2MAPTLMNASMN1; SMN2 | |
| SCHEMBL13951238 | 0.73 | HTR6 (0.39) | ALDH1A1MAPT | |
| SCHEMBL13951239 | 0.73 | FLT3 (0.48) | SYK | |
| SCHEMBL14670736 | 0.69 | BCL6 (0.43) | PKMULK1PTK2PTK2BCDK1 | |
| SCHEMBL16570846 | 0.68 | FGFR4 (0.47) | ULK1PTK2PTK2BCDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2009026107-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | SYK, JAK2, BTK | PKM 1248/4885ULK1 656/4885PTK2 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.